KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 575.8 USD | -0.97% | +1.81% | +9.27% | 11.69% | ||
| 23.06 USD | -0.92% | -0.73% | -24.30% | 11.15% | ||
| 59.27 USD | -1.20% | +2.03% | -5.02% | 8.55% | ||
| 24.16 USD | -1.00% | -1.15% | -11.61% | 8.03% | ||
| 1.875 USD | -0.27% | -13.16% | -67.19% | 6.97% | ||
| 2.64 USD | -0.19% | +1.13% | -20.24% | 4.87% | ||
| 5.22 USD | -1.88% | -7.66% | -47.59% | 4.83% | ||
| 170.1 USD | -0.22% | +4.89% | +9.74% | 4.81% | ||
| 7.32 USD | -4.69% | +17.91% | -14.16% | 4.71% | ||
| 5.34 USD | -0.37% | +0.76% | -61.76% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
